Silvercrest Asset Management Group (NasdaqGM:SAMG) Stock Forecast & Analyst Predictions

Silvercrest Asset Management Group (SAMG) is forecast to grow earnings by 26.7% and revenue by 5.8% annually, outperforming the US market's earnings growth but lagging its revenue growth. The company has a low forecast Return on Equity of 16.4% in three years. Recent updates include increased dividends and analyst price targets, alongside various executive appointments and reporting of quarterly results.

Original reporting
Published Apr 3, 2026, 4:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 3, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Silvercrest Asset Management Group (NasdaqGM:SAMG) Stock Forecast & Analyst Predictions — source image
Decision brief

The 30-second read

$SAMGBullishMed
01

Why it matters

The positive earnings forecast and dividend updates could lead to short-term price appreciation, but underlying profitability metrics suggest cautious optimism.

02

Market read

Moderate relevance for investors focusing on financial sector growth and dividend strategies.

03

What to watch

Potential macroeconomic headwinds or sector-specific challenges could dampen earnings realization, which are not fully accounted for in forecasts.

Relevance 6/10Timing: Short to medium term (3-6 months)

Background

Silvercrest Asset Management Group (SAMG) is a US-based financial services firm specializing in wealth management.

Company-level read

Ticker impact

$SAMGBullishMedium confidence
Context

The news provides a positive outlook on Silvercrest Asset Management Group (SAMG), highlighting forecasted earnings growth of 26.7% and increased dividends, which could influence investor sentiment.

Expected impact

Moderate upward price movement over the next 3-6 months, contingent on earnings realization and dividend sustainability.

Evidence & confidence

The forecasted earnings growth and analyst upgrades indicate positive sentiment; however, the low ROE and moderate revenue growth introduce some caution, leading to a balanced outlook.

Market effects

The financial services sector may experience slight positive momentum due to improved earnings outlooks.

Limited regional impact; primarily relevant to US financial markets.

Minimal global market impact given the company's size and sector focus.

Counterpoint

The low forecast ROE and moderate revenue growth suggest that the stock's valuation may be stretched relative to its profitability, cautioning against aggressive positions.

Key entities

  • Silvercrest Asset Management Group

    A diversified financial services firm focusing on wealth management.

Related articles

$SAMGMed

Silvercrest Asset Management Group Inc. Reports Q2 2026 Results

Silvercrest Asset Management Group Inc. (SAMG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silvercrest Asset Management Group Inc. Reports Q2 2026 Results New York, NY – July 30, 2026 - Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and six months ended Ju

$MRNAHigh

Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge?

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

$VRTXMed

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

$CPIXMedAI 8/10

Cumberland Pharma Reports Phase 2a Safety Data For Ifetroban In Systemic Sclerosis; Shares Slide

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.